BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Risankizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms UltIMMa-2
- Sponsors AbbVie; Boehringer Ingelheim
- 18 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017.
- 13 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2017.